{"id":"https://openalex.org/W1982989509","doi":"https://doi.org/10.1055/s-2006-942761","title":"Pegylated Interferon Therapy for Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders","display_name":"Pegylated Interferon Therapy for Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders","publication_year":2006,"publication_date":"2006-06-01","ids":{"openalex":"https://openalex.org/W1982989509","doi":"https://doi.org/10.1055/s-2006-942761","mag":"1982989509","pmid":"https://pubmed.ncbi.nlm.nih.gov/16810616"},"language":"en","primary_location":{"id":"doi:10.1055/s-2006-942761","doi":"https://doi.org/10.1055/s-2006-942761","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-2006-942761","pdf_url":null,"source":{"id":"https://openalex.org/S96726197","display_name":"Seminars in Thrombosis and Hemostasis","issn_l":"0094-6176","issn":["0094-6176","1098-9064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Seminars in Thrombosis and Hemostasis","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019337932","display_name":"Alfonso Quint\u00e1s\u2010Cardama","orcid":"https://orcid.org/0000-0002-4240-9846","observed_orcids":["https://orcid.org/0000-0002-4240-9846"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alfonso Quint\u00e1s-Cardama","raw_affiliation_strings":["The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA","University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop Kantarjian","raw_affiliation_strings":["The University of Texas M.D. Anderson Cancer Center, Houston, Texas","University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas M.D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061285204","display_name":"Francis Joseph Giles","orcid":"https://orcid.org/0000-0002-6919-0231","observed_orcids":["https://orcid.org/0000-0002-6919-0231"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francis Giles","raw_affiliation_strings":["The University of Texas M.D. Anderson Cancer Center, Houston, Texas","University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas M.D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["The University of Texas M.D. Anderson Cancer Center, Houston, Texas","University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas M.D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":1.234,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.80511585,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"32","issue":"4","first_page":"409","last_page":"416"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pegylated-interferon-alpha","display_name":"pegylated interferon-alpha","score":0.9089999794960022},{"id":"https://openalex.org/keywords/essential-thrombocythemia","display_name":"essential thrombocythemia","score":0.9789999723434448},{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":0.9990000128746033},{"id":"https://openalex.org/keywords/primary-myelofibrosis","display_name":"primary myelofibrosis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.6850000023841858},{"id":"https://openalex.org/keywords/cytoreductive-therapy","display_name":"cytoreductive therapy","score":0.7720000147819519},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.6579999923706055},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7390000224113464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7929468154907227},{"id":"https://openalex.org/C2781057849","wikidata":"https://www.wikidata.org/wiki/Q1368780","display_name":"Essential thrombocythemia","level":3,"score":0.6773872971534729},{"id":"https://openalex.org/C2780829020","wikidata":"https://www.wikidata.org/wiki/Q408163","display_name":"Anagrelide","level":4,"score":0.6510849595069885},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6424442529678345},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.6151959896087646},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.5819621682167053},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.5655539035797119},{"id":"https://openalex.org/C2910274570","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative Disorders","level":2,"score":0.5527960062026978},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5199612379074097},{"id":"https://openalex.org/C2778904597","wikidata":"https://www.wikidata.org/wiki/Q1129111","display_name":"Philadelphia chromosome","level":4,"score":0.5079854130744934},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48425719141960144},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4601796865463257},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4507484436035156},{"id":"https://openalex.org/C2781228144","wikidata":"https://www.wikidata.org/wiki/Q6046441","display_name":"Interferon alfa","level":4,"score":0.44750484824180603},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4387426972389221},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.41430792212486267},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.36843210458755493},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.3334105908870697},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.18684837222099304},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.08682960271835327},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07778969407081604},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007951","descriptor_name":"Leukemia, Myeloid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007951","descriptor_name":"Leukemia, Myeloid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007951","descriptor_name":"Leukemia, Myeloid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009196","descriptor_name":"Myeloproliferative Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009196","descriptor_name":"Myeloproliferative Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009196","descriptor_name":"Myeloproliferative Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010677","descriptor_name":"Philadelphia Chromosome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D010677","descriptor_name":"Philadelphia Chromosome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D010677","descriptor_name":"Philadelphia Chromosome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1055/s-2006-942761","doi":"https://doi.org/10.1055/s-2006-942761","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-2006-942761","pdf_url":null,"source":{"id":"https://openalex.org/S96726197","display_name":"Seminars in Thrombosis and Hemostasis","issn_l":"0094-6176","issn":["0094-6176","1098-9064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Seminars in Thrombosis and Hemostasis","raw_type":"journal-article"},{"id":"pmid:16810616","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16810616","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Seminars in thrombosis and hemostasis","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7599999904632568}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2564965553","https://openalex.org/W2586987584","https://openalex.org/W3159436887","https://openalex.org/W2592106341","https://openalex.org/W3031665482","https://openalex.org/W4405127126","https://openalex.org/W4409962672","https://openalex.org/W1567165257","https://openalex.org/W2570736466","https://openalex.org/W4408909345"],"abstract_inverted_index":{"The":[0,120],"conventional":[1],"management":[2],"of":[3,17,38,50,78,81,122,136,146,151,171],"patients":[4,126,154,174],"with":[5,127,155,175],"high-risk":[6],"Philadelphia":[7],"chromosome-negative":[8],"(Ph-negative)":[9],"myeloproliferative":[10],"disorders":[11],"(MPDs)":[12],"revolves":[13],"around":[14],"the":[15,36,47,86,130,144,147,165,169],"administration":[16,111],"cytoreductive":[18],"agents":[19],"such":[20],"as":[21],"hydroxyurea,":[22],"anagrelide,":[23],"and":[24,43,65,99,117,129,133,149,160],"recombinant":[25],"human":[26],"interferon":[27],"alpha":[28],"(IFN-alpha).":[29],"IFN-alpha":[30,51,71,88,141],"has":[31,142],"shown":[32],"significant":[33],"activity":[34,118,148],"in":[35,101,153,173],"treatment":[37],"chronic":[39],"myelogenous":[40],"leukemia":[41],"(CML)":[42],"Ph-negative":[44,176],"MDPs.":[45],"However,":[46],"response":[48],"rates":[49,60],"therapy":[52],"frequently":[53],"have":[54],"been":[55],"hampered":[56],"by":[57,74],"high":[58],"dropout":[59],"due":[61],"to":[62,85,105,139],"side":[63],"effects":[64],"inconvenient":[66],"dosing":[67],"schedules.":[68],"Pegylated":[69],"(PEG)":[70],"is":[72],"formulated":[73],"covalently":[75],"attaching":[76],"polymers":[77],"ethylene":[79],"glycol":[80],"large":[82],"molecular":[83],"weight":[84],"native":[87],"molecule.":[89],"Such":[90],"chemical":[91],"modification":[92],"increases":[93],"serum":[94],"half-life,":[95],"decreases":[96],"renal":[97],"excretion,":[98],"results":[100],"prolonged":[102],"patient":[103],"exposure":[104],"PEG-IFN-alpha,":[106],"thus":[107],"allowing":[108],"for":[109,125],"weekly":[110],"while":[112],"maintaining":[113],"acceptable":[114],"toxicity,":[115],"tolerability,":[116],"profiles.":[119],"lack":[121],"adequate":[123],"therapies":[124],"MPDs":[128],"superior":[131],"pharmacokinetic":[132],"pharmacodynamic":[134],"profile":[135],"PEG-IFN-alpha":[137,152,172],"relative":[138],"standard":[140],"prompted":[143],"investigation":[145],"safety":[150],"essential":[156],"thrombocythemia,":[157],"polycythemia":[158],"vera,":[159],"idiopathic":[161],"myelofibrosis.":[162],"We":[163],"summarize":[164],"available":[166],"data":[167],"on":[168],"use":[170],"MPDs.":[177]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":3}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}